Open AccessPharmacy-Based Infectious Disease Management Programs Incorporating CLIA-Waived Point-of-Care Tests
Author(s) -
S. R. Herbin,
Donald G. Klepser,
Michael E. Klepser
Publication year - 2020
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.00726-19
Subject(s) - pharmacy , point of care testing , medicine , infectious disease (medical specialty) , human immunodeficiency virus (hiv) , family medicine , utilization management , disease , pathology , health care , political science , law
There are roughly 48,000 deaths caused by influenza annually and an estimated 200,000 people who have undiagnosed human immunodeficiency virus (HIV). These are examples of acute and chronic illnesses that can be identified by employing a CLIA-waived test. Pharmacies across the country have been incorporating CLIA-waived point-of-care tests (POCT) into disease screening and management programs offered in the pharmacy. The rationale behind these programs is discussed. Additionally, a summary of clinical data for some of these programs in the infectious disease arena is provided. Finally, we discuss the future potential for CLIA-waived POCT-based programs in community pharmacies.